ANIPANI Pharmaceuticals, Inc.

Healthcare

$72.60-21% 1Y

$72.60

$70.0852 weeks$95.38

Is the price fair?

Excellent

Undemanding: modest expectations priced in, cheap against its own history, and cheap vs its sector.

3 good

What the price assumes~−4% a year

Priced for a decline (~−4% a year). The price demands less than its three-year revenue growth of 35% a year, expectations look modest.

Vs its own P/E rangecheapest in 19 quartersderived

Cheap vs its own history: P/E 15.7 vs a 61.3 median over 19 quarters (−74% vs median).

Vs sector (EV/EBIT)10.7×

Sector median 25.1× across 135 covered peers. EV/EBIT counts debt as part of the price, so a cash-rich and a borrowed company can be compared on the same footing.

Unless marked, from derived, as of Jun 30, 2026.

Against the whole market›

Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.

P/E (valuation)better than 69% of the market

FCF yieldbetter than 87% of the market

Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.

What ANIP's price assumes

ANI Pharmaceuticals, Inc. trades at 15.7× earnings against 21.0× for the median Drug Manufacturers - Specialty & Generic name, cheaper than its own group.

15.7

Trailing P/E · Drug Manufacturers - Specialty & Generic median 21.0 · cheaper than the typical name in its group

Price / sales: 1.70
Price / sales · today's price, trailing year to Jun 30, 2026
Free cash flow yield: 10%
Free cash flow yield · Drug Manufacturers - Specialty & Generic median 4.9%
Growth the price implies: −4.1%
Growth the price implies · The price pays for −4.1% free cash flow growth a year for a decade; the business has delivered +78% a year over the last three.